Lymph node extramedullary hematopoiesis in breast cancer patients receiving neoadjuvant chemotherapy combined with immunotherapy: A case report
World Journal of Clinical Oncology · 24.06.2026 · 17 (6)
DOI: 10.5306/wjco.121496 ↗Kurz gefasst
Fallbericht in der Zeitschrift World Journal of Clinical Oncology, online erschienen am 24.06.2026. Verfasst von Ping Xing und 5 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND Extramedullary hematopoiesis (EMH) in lymph nodes, particularly following neoadjuvant chemotherapy for breast cancer, is a rare phenomenon. Its occurrence in the context of combined immunochemotherapy remains underreported. Here, we present the first case of trilineage EMH in axillary lymph nodes following neoadjuvant immunochemotherapy for triple-negative breast cancer (TNBC). CASE SUMMARY A patient in her 50 years with newly diagnosed TNBC (cT1N1M0, stage IIA) underwent neoadjuvant therapy with epirubicin/cyclophosphamide and nab-paclitaxel, in combination with the PD-1 inhibitor toripalimab. Post-surgical pathological evaluation revealed a pathological complete response (ypT0N0) in both the breast and axillary lymph nodes, with undetectable circulating tumor DNA. However, histological examination of five axillary lymph nodes identified foci of trilineage EMH, comprising myeloid precursors, erythroblasts, and megakaryocytes, confirmed by immunohistochemistry for MPO, CD71, and CD61. No residual carcinoma or lymphoma was detected. CONCLUSION This case highlights EMH as a rare benign finding after effective neoadjuvant chemoimmunotherapy. The development of EMH likely involves multiple factors: Chemotherapy-induced bone marrow suppression, granulocyte colony-stimulating factor-mediated mobilization, and speculatively PD-1 blockade-related microenvironment remodeling. Recognition prevents misdiagnosis. Direct mechanistic evidence is lacking.
Zitieren
APA
Xing, P., Chen, Z., Jin, H., Luo, H., Gan, M., & Huang, J. (2026). Lymph node extramedullary hematopoiesis in breast cancer patients receiving neoadjuvant chemotherapy combined with immunotherapy: A case report. World Journal of Clinical Oncology, 17(6). https://doi.org/10.5306/wjco.121496
Vancouver
Xing P, Chen Z, Jin H, Luo H, Gan M, Huang J. Lymph node extramedullary hematopoiesis in breast cancer patients receiving neoadjuvant chemotherapy combined with immunotherapy: A case report. World Journal of Clinical Oncology. 2026;17(6). doi:10.5306/wjco.121496
BibTeX
@article{Xing2026,
author = {Xing, Ping and Chen, Zhi-Gang and Jin, Hai-Li and Luo, Hua-Rong and Gan, Mei-Fu and Huang, Jian},
title = {Lymph node extramedullary hematopoiesis in breast cancer patients receiving neoadjuvant chemotherapy combined with immunotherapy: A case report},
journal = {World Journal of Clinical Oncology},
year = {2026},
volume = {17},
number = {6},
doi = {10.5306/wjco.121496}
}
EUVIMED